- Email: [email protected]
4826680 Pharmaceutical composition containing thymus extract fractions
New Patents
iii
ferably the enzyme is catalase, which may be immobilized by adsorption, by absorption, by covalent binding or by antibody complexing.
The novel vaccine has an improved immunogenicity compared with the conventional vaccine.
4826680
4826957
PHARMACEUTICAL COMPOSITION CONTAINING THYMUS EXTRACT FRACTIONS
IMMUNOGENIC RECOMBINANT YEAST EXPRESSION PRODUCT AND METHOD FOR PURIFYING 1T
Karl-Heinz Jaeger, Luzern, Switzerland assigned to Dr Kurt Mulli Nachf GmbH & Co KG A pharmaceutical composition is described, which contains a fraction consisting of low molecular proteins and/or oligo peptides, and a yellow fraction containing riboflavine, which is associated with organ specific oligo peptides, which fractions are obtainable by fractionation of thymus extract. This composition has a significant immuno stimulating activity, and can be used for the treatment of immuno deficiency diseases, as for example, for T-cell-deficiencies.
4826687
Victor Nussenzweig, Philip J Barr assigned to New York University; Chiton Corporati Described is an immunogenicpolypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
4828838 TREATMENT OF HUMAN VIRAL INFECTION Janet L Rideout, David Barry, Sandra Lehrman, Clair Martha St, Phillip A Furman assigned to Burroughs Wellcome Co
INFLUENZA VACCINE Kuniaki Nerome, Akira Oya, Kunio Ohkuma, Atsuo Inoue, Tokyo, Japan assigned to National Institute of Health; Daiichi Seiyaku Co Ltd ]Juridical Foundation the Chemo-SeroTherapeutic Research Institu This invention relates to a novel influenza vaccine comprising a complex of HANA antigen and an MDP derivative. The novel vaccine is prepared by mixing an influenza HANA antigen and at least one MDP derivative in a suitable medium; solubilizingthe resulting mixture with a surface active agent capable of being removed by dialysis, the solubilization being conducted in the presence or absence of cholesterol, lecithin and dicetyl phosphate or a mixture thereof; and then removing the surface active agent therefrom by dialysis to obtain an influenza vaccine comprising artificial vesicle-like particles of a complex of HANA antigen and MDP derivative, where the MDP derivative forms a membrane of the particle (corresponding to the lipid membrane of natural influenza virus particle) on the surface of which there exists the HANA antigen being bonded to the MDP derivative so as to form the complex. Thus, said artificial vesiclelike particle of the HANA antigen-MDP derivative complex has nearly the same particle size and shape as the natural influenza virus particle. CIMID 13/I--D
Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidineor a pharmaceutically acceptable basic salt thereof for the same purpose.
4828985 ANTIBODIES AGAINST THE COMPLEX OF A SMALL MOLECULE AND ITS BINDING PROTEIN, THEIR PREPARATION AND THEIR USE IN DIAGNOSTIC METHODS Colin H Self, Ealing, United Kingdom assigned to Cambridge Patent Developments Limited The invention involves polyclonal antibodies reactive with a complex of a hapten and its binding protein, wherein the antibodies are unreactive with the free hapten or free binding protein. The antibodies are useful in assays of the hapten or the binding protein.
iii
ferably the enzyme is catalase, which may be immobilized by adsorption, by absorption, by covalent binding or by antibody complexing.
The novel vaccine has an improved immunogenicity compared with the conventional vaccine.
4826680
4826957
PHARMACEUTICAL COMPOSITION CONTAINING THYMUS EXTRACT FRACTIONS
IMMUNOGENIC RECOMBINANT YEAST EXPRESSION PRODUCT AND METHOD FOR PURIFYING 1T
Karl-Heinz Jaeger, Luzern, Switzerland assigned to Dr Kurt Mulli Nachf GmbH & Co KG A pharmaceutical composition is described, which contains a fraction consisting of low molecular proteins and/or oligo peptides, and a yellow fraction containing riboflavine, which is associated with organ specific oligo peptides, which fractions are obtainable by fractionation of thymus extract. This composition has a significant immuno stimulating activity, and can be used for the treatment of immuno deficiency diseases, as for example, for T-cell-deficiencies.
4826687
Victor Nussenzweig, Philip J Barr assigned to New York University; Chiton Corporati Described is an immunogenicpolypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
4828838 TREATMENT OF HUMAN VIRAL INFECTION Janet L Rideout, David Barry, Sandra Lehrman, Clair Martha St, Phillip A Furman assigned to Burroughs Wellcome Co
INFLUENZA VACCINE Kuniaki Nerome, Akira Oya, Kunio Ohkuma, Atsuo Inoue, Tokyo, Japan assigned to National Institute of Health; Daiichi Seiyaku Co Ltd ]Juridical Foundation the Chemo-SeroTherapeutic Research Institu This invention relates to a novel influenza vaccine comprising a complex of HANA antigen and an MDP derivative. The novel vaccine is prepared by mixing an influenza HANA antigen and at least one MDP derivative in a suitable medium; solubilizingthe resulting mixture with a surface active agent capable of being removed by dialysis, the solubilization being conducted in the presence or absence of cholesterol, lecithin and dicetyl phosphate or a mixture thereof; and then removing the surface active agent therefrom by dialysis to obtain an influenza vaccine comprising artificial vesicle-like particles of a complex of HANA antigen and MDP derivative, where the MDP derivative forms a membrane of the particle (corresponding to the lipid membrane of natural influenza virus particle) on the surface of which there exists the HANA antigen being bonded to the MDP derivative so as to form the complex. Thus, said artificial vesiclelike particle of the HANA antigen-MDP derivative complex has nearly the same particle size and shape as the natural influenza virus particle. CIMID 13/I--D
Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of 5'-mono-, di- and triphosphate of 3'-azido-3'-deoxythymidineor a pharmaceutically acceptable basic salt thereof for the same purpose.
4828985 ANTIBODIES AGAINST THE COMPLEX OF A SMALL MOLECULE AND ITS BINDING PROTEIN, THEIR PREPARATION AND THEIR USE IN DIAGNOSTIC METHODS Colin H Self, Ealing, United Kingdom assigned to Cambridge Patent Developments Limited The invention involves polyclonal antibodies reactive with a complex of a hapten and its binding protein, wherein the antibodies are unreactive with the free hapten or free binding protein. The antibodies are useful in assays of the hapten or the binding protein.